Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis

M. Anderson, D. Moore, Douglas F Larson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Isoproterenol (Iso) was a clinical therapeutic that is now used as a research means for the induction of cardiac hypertrophy. Currently, dobutamine (Dob) has replaced Iso as the preferred inotropic β-adrenergic agent to wean patients from cardiopulmonary bypass and to sustain adequate cardiac function during the postoperative period. We sought to compare the cardiac structural and functional effects of long-term administration (7days) of Iso with Dob at a dose of 40μg/ mouse/day in 12-week-old C57BL/6 female mice. Cardiac function was determined with transthoracic echo cardiography (ECHO) 24 hours after the last dose. Cardiac wet weights increased 33% and 24% in the Iso and Dob groups compared with controls (p < 0.05). Dob and Iso significantly increased cardiac fibrosis and decreased cardiac function with chronic administration. Administration also resulted in increased left atrial size, suggesting that both Dob and Iso decreased LV compliance, but did not induce heart failure. In conclusion, chronic administration of Dob may have a detrimental effect on cardiac structure and function.

Original languageEnglish (US)
Pages (from-to)231-235
Number of pages5
JournalPerfusion
Volume23
Issue number4
DOIs
StatePublished - 2008

Fingerprint

Dobutamine
Cardiomegaly
Isoproterenol
induction
Fibrosis
Echocardiography
Cardiopulmonary Bypass
Postoperative Period
Adrenergic Agents
Compliance
Heart Failure
Weights and Measures
Group
Research

Keywords

  • β-adrenergic
  • Cardiac
  • Echocardiogram
  • Extracellular matrix
  • Fibrosis
  • Remodeling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging
  • Advanced and Specialized Nursing
  • Safety Research

Cite this

Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis. / Anderson, M.; Moore, D.; Larson, Douglas F.

In: Perfusion, Vol. 23, No. 4, 2008, p. 231-235.

Research output: Contribution to journalArticle

@article{6d03c8f438b444a8b7685c530f95f638,
title = "Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis",
abstract = "Isoproterenol (Iso) was a clinical therapeutic that is now used as a research means for the induction of cardiac hypertrophy. Currently, dobutamine (Dob) has replaced Iso as the preferred inotropic β-adrenergic agent to wean patients from cardiopulmonary bypass and to sustain adequate cardiac function during the postoperative period. We sought to compare the cardiac structural and functional effects of long-term administration (7days) of Iso with Dob at a dose of 40μg/ mouse/day in 12-week-old C57BL/6 female mice. Cardiac function was determined with transthoracic echo cardiography (ECHO) 24 hours after the last dose. Cardiac wet weights increased 33{\%} and 24{\%} in the Iso and Dob groups compared with controls (p < 0.05). Dob and Iso significantly increased cardiac fibrosis and decreased cardiac function with chronic administration. Administration also resulted in increased left atrial size, suggesting that both Dob and Iso decreased LV compliance, but did not induce heart failure. In conclusion, chronic administration of Dob may have a detrimental effect on cardiac structure and function.",
keywords = "β-adrenergic, Cardiac, Echocardiogram, Extracellular matrix, Fibrosis, Remodeling",
author = "M. Anderson and D. Moore and Larson, {Douglas F}",
year = "2008",
doi = "10.1177/0267659108100708",
language = "English (US)",
volume = "23",
pages = "231--235",
journal = "Perfusion",
issn = "0267-6591",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis

AU - Anderson, M.

AU - Moore, D.

AU - Larson, Douglas F

PY - 2008

Y1 - 2008

N2 - Isoproterenol (Iso) was a clinical therapeutic that is now used as a research means for the induction of cardiac hypertrophy. Currently, dobutamine (Dob) has replaced Iso as the preferred inotropic β-adrenergic agent to wean patients from cardiopulmonary bypass and to sustain adequate cardiac function during the postoperative period. We sought to compare the cardiac structural and functional effects of long-term administration (7days) of Iso with Dob at a dose of 40μg/ mouse/day in 12-week-old C57BL/6 female mice. Cardiac function was determined with transthoracic echo cardiography (ECHO) 24 hours after the last dose. Cardiac wet weights increased 33% and 24% in the Iso and Dob groups compared with controls (p < 0.05). Dob and Iso significantly increased cardiac fibrosis and decreased cardiac function with chronic administration. Administration also resulted in increased left atrial size, suggesting that both Dob and Iso decreased LV compliance, but did not induce heart failure. In conclusion, chronic administration of Dob may have a detrimental effect on cardiac structure and function.

AB - Isoproterenol (Iso) was a clinical therapeutic that is now used as a research means for the induction of cardiac hypertrophy. Currently, dobutamine (Dob) has replaced Iso as the preferred inotropic β-adrenergic agent to wean patients from cardiopulmonary bypass and to sustain adequate cardiac function during the postoperative period. We sought to compare the cardiac structural and functional effects of long-term administration (7days) of Iso with Dob at a dose of 40μg/ mouse/day in 12-week-old C57BL/6 female mice. Cardiac function was determined with transthoracic echo cardiography (ECHO) 24 hours after the last dose. Cardiac wet weights increased 33% and 24% in the Iso and Dob groups compared with controls (p < 0.05). Dob and Iso significantly increased cardiac fibrosis and decreased cardiac function with chronic administration. Administration also resulted in increased left atrial size, suggesting that both Dob and Iso decreased LV compliance, but did not induce heart failure. In conclusion, chronic administration of Dob may have a detrimental effect on cardiac structure and function.

KW - β-adrenergic

KW - Cardiac

KW - Echocardiogram

KW - Extracellular matrix

KW - Fibrosis

KW - Remodeling

UR - http://www.scopus.com/inward/record.url?scp=60349114184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60349114184&partnerID=8YFLogxK

U2 - 10.1177/0267659108100708

DO - 10.1177/0267659108100708

M3 - Article

C2 - 19181756

AN - SCOPUS:60349114184

VL - 23

SP - 231

EP - 235

JO - Perfusion

JF - Perfusion

SN - 0267-6591

IS - 4

ER -